Research programme: ion channel inhibitor - Enveda Biosciences
Latest Information Update: 05 Jan 2024
At a glance
- Originator Enveda Biosciences
- Class Analgesics; Skin disorder therapies; Small molecules
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pain; Skin disorders
Most Recent Events
- 21 Dec 2023 Research programme: ion channel inhibitors - Enveda Biosciences is available for licensing as of 21 Dec 2023 (Enveda Biosciences pipeline, December 2023)
- 21 Dec 2023 Preclinical trials in Pain in USA prior to December 2023 (PO) (Enveda Biosciences pipeline, December 2023)
- 21 Dec 2023 Preclinical trials in Skin disorders in USA prior to December 2023 (Topical) (Enveda Biosciences pipeline, December 2023)